Skip to Content
MilliporeSigma
All Photos(2)

Key Documents

L5918

Sigma-Aldrich

Lomustine

≥98%

Synonym(s):

1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea

Sign Into View Organizational & Contract Pricing

Select a Size

100 MG
$161.04

$161.04

List Price$176.00Save 9%
Web-Only Promotion

Available to ship onApril 15, 2025Details


Request a Bulk Order

Select a Size

Change View
100 MG
$161.04

About This Item

Empirical Formula (Hill Notation):
C9H16ClN3O2
CAS Number:
Molecular Weight:
233.70
EC Number:
MDL number:
UNSPSC Code:
12352100
PubChem Substance ID:
NACRES:
NA.25

$161.04

List Price$176.00Save 9%
Web-Only Promotion

Available to ship onApril 15, 2025Details


Request a Bulk Order

assay

≥98%

storage temp.

−20°C

SMILES string

ClCCN(N=O)C(=O)NC1CCCCC1

InChI

1S/C9H16ClN3O2/c10-6-7-13(12-15)9(14)11-8-4-2-1-3-5-8/h8H,1-7H2,(H,11,14)

InChI key

GQYIWUVLTXOXAJ-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Antineoplastic agent with cellular DNA effects. Lomustine induces p53 expression in A2870 cells.

pictograms

Skull and crossbonesHealth hazard

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 3 Oral - Carc. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Joann L Ater et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(21), 2641-2647 (2012-06-06)
PURPOSE Surgery is curative therapy for pediatric low-grade gliomas (LGGs) in areas of the brain amenable to complete resection. However, LGGs located in areas where complete resection is not possible can threaten both function and life. The purpose of this
Enrico Franceschi et al.
Neuro-oncology, 14(12), 1503-1510 (2012-10-24)
The treatment of patients with recurrent glioblastoma remains a major oncologic problem, with median survival after progression of 7-9 months. To determine the maximum tolerated dose and dose-limiting toxicity (DLT), the combination of dasatinib and cyclonexyl-chloroethyl-nitrosourea (CCNU) was investigated in
Carsten Friedrich et al.
European journal of cancer (Oxford, England : 1990), 49(4), 893-903 (2012-11-28)
Medulloblastoma in adulthood is rare. Knowledge is limited, and the efficacy and toxicity of chemotherapy--especially in nonmetastatic disease--is still elusive. Seventy adults aged ≥21 years (median age: 28.5 years) with nonmetastatic medulloblastoma were followed as observational patients within the prospective
Roger J Packer et al.
Neuro-oncology, 15(1), 97-103 (2012-10-27)
The purpose of the trial was to determine the survival and incidence of secondary tumors in children with medulloblastoma receiving radiotherapy plus chemotherapy. Three hundred seventy-nine eligible patients with nondisseminated medulloblastoma between the ages of 3 and 21 years were
Tracy T Batchelor et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(26), 3212-3218 (2013-08-14)
A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recent in in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as monotherapy

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service